Reading the latest edition of Pandemic Times published by NTI.
________
Source: Investor Place
Bavarian Nordic (BVNRY) Stock Jumps 70% on Monkeypox Vaccine Order
The monkeypox outbreak is sending BVNRY stock soaring
By Samuel O'Brient | May 20, 2022
Bavarian Nordic (BVNRY) Stock Jumps 70% on Monkeypox Vaccine Order
The monkeypox outbreak is sending BVNRY stock soaring
By Samuel O'Brient | May 20, 2022
• Cases of monkeypox are spreading in the U.S., Canada and Europe
• Danish drugmaker Bavarian Nordic (OTCMKTS: BVNRY) produces a vaccine for the virus
• BVNRY stock is surging after a large vaccine order from Europe
Source: shutterstock.com/PhotobyTawat
For the first time since 2020, a new disease is in focus today. Cases of monkeypox are spreading throughout the U.S. and Canada, as well as multiple European countries. The rare virus is typically found in forest regions of Africa. Now these scattered cases have led to alarm in some communities. However, Danish pharmaceutical producer Bavarian Nordic (OTCMKTS: BVNRY) has an effective vaccine. Both the U.S. and Europe have already placed orders, sending BVNRY stock soaring.
What's Happening With BVNRY Stock
News of the monekypox outbreak has only been trending for the past two days. Since it has, BVNRY stock has been shooting up. Shares began climbing yesterday, but today, as reports increased, they began to skyrocket. While shares have since cooled off slightly, the momentum remains strong. As of this writing, BVNRY stock is up more than 68% for the day. But this could be just the beginning of its new growth trajectory.
Let's take a closer look at the forces driving BVNRY stock up.
Why It Matters
Bavarian Nordic claims to be the only pharmaceutical producer to successfully gain regulatory approval for a monkeypox vaccine. The European country that placed the vaccine order has not been disclosed, but it won't be the only one. The virus has been detected in Spain and Portugal, as well as part of the U.K., and it is authorized for use across Europe and the U.S.
Every country with cases will likely stock up on the vaccine to prevent further spread. While data is still being collected on the virus, it doesn't seem as though the virus poses an immediate threat to the general public. But in the wake of the Covid-19 pandemic, governments aren't willing to take any chances on their nation becoming the breeding ground for the next public health emergency. Even as a precautionary measure, governments will be placing orders within the coming days. And when they do, BVNRY stock will shoot up even further.
The fact that the U.S. quickly placed a $119 million order as part of a larger vaccine contract with Bavarian Nordic should serve as an indicator of how seriously countries are taking the growing threat.
Please go to Investor Place to read more.
________
More:
More:
Inking the orders:
The market for the monkeypox vaccine has been prepped well in advance so when the pandemic hits the vaccines can be sold. It's like creating a market for a product in this case monkeypox scare with the vaccines ready to go with investors lined up.
Commercial warfare over patents between Bavarian Nordic and the British firm Acambis of patent infringement:
Building the biosecurity state one induced pandemic at a time. How these people are able to coordinate all this is actually kind of phenomenal:
Note to readers: Google is censoring this blog.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.